Abstract: Gelled or solid antiperspirant compositions comprising an antiperspirant compound, a borate crosslinker, a hydrophilic polymeric binder, a carrier, and, optionally, a softening agent, are disclosed.

Abstract: Two-component pharmaceutical compositions for topical application to the human or animal body comprising two miscible liquid phases having different lipophilicities and a drug dissolved in at least one liquid phase, each phase comprising at least one topically acceptable non-aqueous and non-volatile solvent.

Abstract: Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment or prevention of neurodegenerative disorders or neurotoxic injuries utilizing them.

Abstract: 6,7-propylene-, butylene-, or pentylene-bridged imidazopyridin-4-amines and their intermediate compounds are described. Also disclosed are pharmaceutical compositions containing such compounds and methods of inducing interferon (.alpha.) biosynthesis and treating vital infections involving the use of such compounds.

Abstract: The invention is herbicide 3-substituted quinoline intermediates and a method for the synthesis of the herbicide intermediates 3-alkoxymethyl substituted quinolines.

Abstract: A compound of the formula I in which ##STR1## Z is O or S; R.sup.11 is a halogen atom;R.sup.12 is a halogen atom or a trifluoromethyl group; andX is S, SO, SO.sub.2, O or NH;R.sup.4 is naphthyl, quinolinyl, benzimidazolyl, pyridyl, pyradazinyl, benzoxazolyl or benzothiazolyl, unsubstituted or substituted by one or two substituents selected from a halogen atom, (1-4C)alkyl, (1-4C)alkoxy, nitro, (1-4C)alkoxycarbonyl, halo(1-4C)alkyl, and phenyl;or a pharmaceutically acceptable salt thereof.The compounds are useful as inhibitors of amyloid beta-protein production.

Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.

Abstract: A series of benzoquinolin-3-ones are pharmaceuticals effective in treating conditions consequent on both Type I and Type II 5.alpha.-reductase.

Abstract: Stick formulations for topical delivery of water soluble and/or water insoluble agents are disclosed. The stick formulations may contain steroids, antibiotics, antifungals, antihistamines anti inflammatories or local anesthetics. The vehicles comprise a combination of waxes and oils and a surfactant in embodiments involving water soluble agents. Methods for preparing the various stick formulations are also disclosed.

Abstract: Combatting fungi and bacteria with quinoline derivatives of the formula ##STR1## in which X is a nitrogen atom and Y is a CH-group orY is a nitrogen atom and X is a CH-group,R is hydrogen, halogen, acetyl or alkyl which is optionally substituted by one to three radicals independently selected from the group consisting of alkoxy, phenyl, hydroxy, halogen and cyano, orR is alkenyl which is optionally substituted by one to three radicals independently selected from the group consisting of halogen, cyano, alkoxy, phenyl and hydroxy, orR is alkynyl which is optionally substituted by one to three radicals independently selected from the group consisting of halogen, phenyl, trimethylsilyl, hydroxy, cyano, alkoxy, alkylamino, dialkylamino, alkylcarbonyl, tolyl, alkoxycarbonyl and alkylcarbonyloxy, orR is cycloalkyl which is optionally substituted by one to three radicals independently selected from the group consisting of halogen and cyano,A is hydrogen or halogen andB is halogen or halogenoalkyl,or an acid addition

Abstract: Benzo[5.6]pyrano[2.3.4-ij]quinolizine and benzo[5.6]thiopyrano[2.3.4-ij]quinolizine compounds having the formula ##STR1## wherein A is sulfur or oxygen; R.sup.1 is selected from the group consisting of hydroxy, protected-hydroxy, C.sub.1 -C.sub.6 -alkoxy, halo, amino, C.sub.1 -C.sub.6 -alkylamino, hydroxy-C.sub.1 -C.sub.6 -alkylamino, bicyclic nitrogen-containing heterocycle, nitrogen-containing aromatic heterocycle, and nitrogen-containing heterocycle; R.sup.2 is selected from the group consisting of hydrogen, halo, C.sub.1 -C.sub.6 -alkyl, or halo-C.sub.1 -C.sub.6 -alkyl; R.sup.3 is selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 -alkyl or C.sub.5 -C.sub.7 -cycloalkyl; and R.sup.4 and R.sup.5 are independently selected from the group consisting of hydrogen, C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.

Abstract: The present invention relates to oil-in-water emulsion compositions useful for topical application to human skin. These compositions comprise from about 5% to about 60% by weight of the total composition of an oil phase having a viscosity from about 3000 cps to about 10,000,000 cps, wherein the oil phase comprises from about 0.1% to about 10% by weight of the total composition of a particulate thickener for the oil phase, and from 0% to about 10% by weight of the total composition of an oil phase emulsifier. These compositions also comprise from about 40% to about 95% by weight of the total composition of an aqueous phase selected from the group consisting of water, water-miscible solvents, and mixtures thereof, wherein the aqueous phase comprises from 0% to about 10% by weight of the total composition of an aqueous phase emulsifier. In these compositions the weight percentages of the oil phase emulsifier and of the aqueous phase emulsifer are not simultaneously zero.

Abstract: A topically administrable pharmaceutical composition comprising (A) zinc phthalocyanine complex, (B) as carrier for the complex, (i) a N-alkylpyrrolidone together with a pharmaceutically acceptable co-solvent for the complex, (ii) dimethyl sulphoxide or a mixture thereof with a pharmaceutically acceptable co-solvent for the complex, (iii) a liposome, or (iv) a N,N-dialkylbenzamide or a mixture thereof with a pharmaceutically acceptable co-solvent for the complex, and (C) a gelling agent.

Abstract: Substituted N-arylmethyl and heterocyclylmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines, pharmaceutical compositions containing them and methods for a) effecting c-GMP-phosphodiesterase inhibition, b) treating heart failure and/or hypertension, c) reversing or reducing nitrate-induced tolerance and d) treating angina pectoris, congestive heart disease and myocardial infarction utilizing them.

Abstract: Compounds of the formula I ##STR1## and the corresponding 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine derivatives, their physiologically acceptable salts and/or solvates, inhibit the binding of fibrinogen to the corresponding receptor and can be used for the treatment of thromboses, osteoporosis, oncoses, stroke, myocardial infarct, inflammations, arteriosclerosis and osteolytic disorders.

Abstract: A tricyclic compound represented by the following formula (I): ##STR1## exhibits antagonism to angiotensin II receptors.

Abstract: This invention provides a novel series of substituted pyrrolidines which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.

Abstract: Provided is a deodorant gel composition having improved mildness to the skin through the use of increased level of water and polyethylene glycol solvent, such composition comprising (a) from about 0.001% to about 20%, by weight, of deodorant active, fragrance, or a combination thereof; (b) from about 0.1% to about 15%, by weight, of a soap gelling agent selected from the group consisting of salts of C.sub.12 -C.sub.40 fatty acids, and combinations thereof; (c) a hydrogel component comprising from about 0.001% to about 5%, by weight of the composition, of hydrogel forming crosslinked polymeric gelling agent, said hydrogel forming polymeric gelling agent being incorporated in said composition as a gel; (d) from about 5% to about 70%, by weight, of a polyhydroxy solvent for said soap gelling agent, said polyhydroxy solvent being selected from the group consisting of: alkyl alcohols having at least three hydroxy groups; polymers of C.sub.3 -C.sub.

Abstract: Disclosed are novel cannabinoid (CB2) receptor agonists, their compositions, and the methods of their preparation. The compounds are useful for lowering ocular intra ocular pressure, treating glaucoma, useful as antiinflammatory, immunosuppressive, analgesics agents, and as agents for treatment and prevention of emesis and nausea because of the activity on the cannabinoid receptor.

Abstract: Compounds useful in the treatment of inflammatory disorders, central nervous system disorders and other disorders of the formula I ##STR1## and the pharmaceutically-acceptable salts thereof, wherein Ar.sup.1 and Ar.sup.2 are each independently aryl or substituted aryl; R.sup.1 is alkyl having from 1 to 6 carbon atoms;R.sup.